WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2004035080) TREATMENT OF HYPERSENSITIVITY CONDITIONS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2004/035080    International Application No.:    PCT/AU2003/001374
Publication Date: 29.04.2004 International Filing Date: 16.10.2003
Chapter 2 Demand Filed:    14.05.2004    
IPC:
A61K 38/12 (2006.01)
Applicants: THE UNIVERSITY OF QUEENSLAND [AU/AU]; BRISBANE, Queensland 4072 (AU) (For All Designated States Except US).
SHIELS, Ian, Alexander [AU/AU]; (AU) (For US Only).
TAYLOR, Stephen, Maxwell [AU/AU]; (AU) (For US Only)
Inventors: SHIELS, Ian, Alexander; (AU).
TAYLOR, Stephen, Maxwell; (AU)
Agent: GRIFFITH HACK; 509 St Kilda Road, MELBOURNE, Victoria 3004 (AU)
Priority Data:
2002952129 17.10.2002 AU
Title (EN) TREATMENT OF HYPERSENSITIVITY CONDITIONS
(FR) TRAITEMENT D'ETATS D'HYPERSENSIBILITE
Abstract: front page image
(EN)This invention relates to methods of treatment of hypersensitivity conditions such as asthma and other allergic conditions, and especially to treatment of these conditions with cyclic peptidic and peptidomimetic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably act as antagonists of the C5a receptor, and are active against C5a receptors on polymorphonuclear leukocytes and macrophages. Particularly preferred compounds for use in the methods of the invention are disclosed.
(FR)L'invention concerne des procédés de traitement d'états d'hypersensibilité tels que l'asthme et autres états allergiques, et notamment des procédés de traitement de ces états à l'aide de composés peptidiques et peptidomimétiques cycliques aptes à moduler l'activité des récepteurs couplés à une protéine G. Ces composés, de préférence, agissent comme antagonistes du récepteur C5a, et sont actifs contre les récepteurs C5a de leucocytes et macrophages polymorphonucléaires. L'invention concerne enfin les composés préférés utilisés dans ces procédés.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)